Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin alfa dosing in chemotherapy-induced anemia
NCT00118638Phase 3Completed
- Sponsor
- Amgen
- Start
- Mar 2004
- Primary completion
- Dec 2004
- Modality
- Erythropoietins, Colony Stimulating Factors
01
Overview
Phase 3, randomised, double-blind trial of darbepoetin alfa in anemia (2 arms), sponsored by Amgen. Primary endpoint: Incidence of at least one RBC transfusion from week 5 to End of Treatment Period. Started Mar 2004; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00118638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00118638.